Clinical trials: Sarcoidosis
Sarcoidosis, Pulmonary
A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis
This is a multicenter, single-arm, unblinded/open-label study of the effect size of HRCT endpoints in response to glucocorticoid induction therapy in subjects with a diagnosis of pulmonary sarcoidosis who have not received…
- Trial name
- NCT03324503
- Testing
- Glucocorticoid (prednisone or prednisolone)
- Where
- 20 sites in United States, Netherlands and 1 more
- Volunteers
- 8 people
- Sponsor
- Celgene
Pulmonary Sarcoidosis
An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
Open-label Study to Evaluate the Long-term Safety and Durability of Effect of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extra-pulmonary Involvement
- Trial name
- NCT06169397
- Testing
- XTMAB-16
- Where
- 11 sites in United States, Czechia and 2 more
- Volunteers
- 31 people
- Sponsor
- Xentria, Inc.
Lung Cancer, Emphysema
CryoSpray Ablation(tm)Thoracic Patient Registry
The purpose of this study is to create a patient registry to collect and analyze information on subjects treated with the CryoSpray Ablation™ System post-510K approval.
- Conditions
- Lung Cancer, Emphysema, Chronic Bronchitis, COPD
- Trial name
- NCT00785239
- Sponsor
- CSA Medical, Inc.
Sarcoidosis, Pulmonary
Acthar Gel in Participants With Pulmonary Sarcoidosis
The purpose of this study is to find out if Acthar Gel is safe and effective to treat pulmonary sarcoidosis. Participants will be randomly assigned (like flipping a coin) to receive a shot under their skin of Acthar Gel or a…
- Trial name
- PULSAR (NCT03320070)
- Testing
- Acthar Gel
- Where
- 29 sites in United States
- Volunteers
- 55 people
- Sponsor
- Mallinckrodt
Neoplasms
Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six Doses
Although Neopharm has terminated its sponsorship of this study, it is continuing under the sponsorship of the NCI. Please contact Raffit Hassan, MD at 301-451-8742 for more information.
- Trial name
- NCT00024687
- Testing
- SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin
- Where
- United States
- Sponsor
- INSYS Therapeutics Inc
Pulmonary Sarcoidosis
Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis
The purpose of this proof of concept study was to determine whether CMK389 displays the safety and efficacy profile to support further development in chronic pulmonary sarcoidosis.
- Trial name
- NCT04064242
- Testing
- CMK389
- Where
- 22 sites in United States, Czechia and 4 more
- Volunteers
- 62 people
- Sponsor
- Novartis Pharmaceuticals
Lung Diseases, Interstitial
Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) Epidemiology Non-interventional Study (NIS)
This study aims to characterize the epidemiology of interstitial lung diseases (ILD) associated to connective tissue disease (CTD) in Mexico, and to study its correlation with the different comorbidities and treatments used, as…
- Trial name
- NCT05819385
- Where
- Mexico
- Volunteers
- 312 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Sarcoidosis
Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations
Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients with Pulmonary Sarcoidosis with or Without Extrapulmonary Manifestations
- Trial name
- NCT05890729
- Where
- 33 sites in United States, Czechia and 4 more
- Volunteers
- 32 people
- Sponsor
- Xentria, Inc.
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
This study assesses the safety and efficacy of bardoxolone methyl relative to placebo in patients with pulmonary hypertension to determine the recommended dose range, evaluate the change from baseline in 6-minute walk distance…
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Hypertension, Interstitial Lung Disease, Idiopathic Interstitial Pneumonia
- Trial name
- NCT02036970
- Testing
- Bardoxolone methyl
- Where
- 32 sites in United States, Germany
- Volunteers
- 166 people
- Sponsor
- Biogen
Idiopathic Pulmonary Fibrosis (IPF), Sarcoidosis Lung
A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects on Oral Medications for the Treatment of Interstitial Lung Disease, Sarcoid and Pulmonary Hypertension
This study will evaluate whether participants with serious lung diseases such as idiopathic pulmonary fibrosis, sarcoidosis, and pulmonary hypertension who use the FORTISKAP™ smart medication cap - a bottle-top device that tracks…
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF), Sarcoidosis Lung, Pulmonary Hypertension, Usual Interstitial Pneumonia
- Trial name
- NCT07613216
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Cosmos Rx, Inc
Pulmonary Sarcoidosis
A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis
The study proposes to evaluate the safety, tolerability, and efficacy of PD 0360324 in subjects with chronic pulmonary sarcoidosis inadequately treated with standard of care therapies.
- Trial name
- NCT01732211
- Testing
- PD 0360324, Normal Saline for injection
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
Sarcoidosis Associated Pulmonary Hypertension
LAM-001 for the Treatment of Sarcoidosis Associated Pulmonary Hypertension (SAPH)
A Phase 2, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LAM-001 (Inhaled Sirolimus) in Adults with Sarcoidosis Associated Pulmonary Hypertension (SAPH)
- Trial name
- NCT07886554
- Testing
- LAM-001
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- IRulya Therapeutics Inc.
Sarcoidosis
A Study of Infliximab in Patients With Sarcoidosis
The purpose of this study is to evaluate the safety and effectiveness of infliximab (Remicade) in patients with Chronic Sarcoidosis.
- Trial name
- NCT00073437
- Testing
- Infliximab
- Volunteers
- 139 people
- Sponsor
- Centocor, Inc.
Pulmonary Sarcoidosis
Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
This is a multicenter, randomized, double-blind, placebo-controlled, study comparing the efficacy and safety of intravenous (IV) efzofitimod 3 mg/kg and 5 mg/kg versus placebo after 48 weeks of treatment.
- Trial name
- NCT05415137
- Testing
- Efzofitimod 3 mg/kg, Efzofitimod 5 mg/kg
- Where
- 91 sites in United States, Brazil and 7 more
- Volunteers
- 268 people
- Sponsor
- aTyr Pharma, Inc.